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Abstract
Background: Sepsis remains a common and serious condition with significant morbidity and mortality due to
multiple organ dysfunction, especially acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).
Sepsis-induced ALI is characterized by injury and dysfunction of the pulmonary microvasculature and pulmonary
microvascular endothelial cells (PMVEC), resulting in enhanced pulmonary microvascular sequestration and pulmonary
infiltration of polymorphonuclear leukocytes (PMN) as well as disruption of the normal alveolo-capillary permeability
barrier with leak of albumin-rich edema fluid into pulmonary interstitium and alveoli. The role of PMVEC death and
specifically apoptosis in septic pulmonary microvascular dysfunction in vivo has not been established.
Methods: In a murine cecal ligation/perforation (CLP) model of sepsis, we quantified and correlated time-dependent
changes in pulmonary microvascular Evans blue (EB)-labeled albumin permeability with (1) PMVEC death (propidium
iodide [PI]-staining) by both fluorescent intravital videomicroscopy (IVVM) and histology, and (2) PMVEC apoptosis
using histologic fluorescent microscopic assessment of a panel of 3 markers: cell surface phosphatidylserine (detected
by Annexin V binding), caspase activation (detected by FLIVO labeling), and DNA fragmentation (TUNEL labeling).
Results: Compared to sham mice, CLP-sepsis resulted in pulmonary microvascular barrier dysfunction, quantified by
increased EB-albumin leak, and PMVEC death (PI+ staining) as early as 2 h and more marked by 4 h after CLP. Septic
PMVEC also exhibited increased presence of all 3 markers of apoptosis (Annexin V+, FLIVO+, TUNEL+) as early as
30 mins – 1 h after CLP-sepsis, which all similarly increased markedly until 4 h. The time-dependent changes in septic
pulmonary microvascular albumin-permeability barrier dysfunction were highly correlated with PMVEC death
(PI+; r = 0.976, p < 0.01) and PMVEC apoptosis (FLIVO+; r = 0.991, p < 0.01). Treatment with the pan-caspase
inhibitor Q-VD prior to CLP reduced PMVEC death/apoptosis and attenuated septic pulmonary microvascular
dysfunction, including both albumin-permeability barrier dysfunction and pulmonary microvascular PMN
sequestration (p < 0.05). Septic PMVEC apoptosis and pulmonary microvascular dysfunction were also abrogated
following CLP-sepsis in mice deficient in iNOS (Nos2−/−) or NADPH oxidase (p47phox−/− or gp91phox−/−) and in wild-type
mice treated with the NADPH oxidase inhibitor, apocynin.
Conclusions: Septic murine pulmonary microvascular dysfunction in vivo is due to PMVEC death, which is mediated
through caspase-dependent apoptosis and iNOS/NADPH-oxidase dependent signaling.
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Introduction
Sepsis remains a common and serious clinical problem
with significant morbidity and mortality. It is estimated
that one million cases of sepsis occur annually in North
America, resulting in death in 20–30 % of cases, such that
sepsis is the most common cause of mortality in Intensive
Care Units (ICUs) and hospitalized patients [1–3]. More-
over, sepsis is a significant healthcare burden, as it con-
sumes up to 45 % of total ICU costs [2, 4]. Morbidity/
mortality in sepsis are principally due to injury and dys-
function of multiple organs, most commonly acute lung
injury (ALI)/acute respiratory distress syndrome (ARDS)
[2, 4–6]. Advances in our understanding of the patho-
physiology of sepsis and organ dysfunction through basic
and clinical research efforts have not significantly im-
proved sepsis outcomes, as the treatment of sepsis and re-
lated organ dysfunction remains largely supportive care
[6–8]. Indeed, clinical trials of novel anti-inflammatory
therapeutic approaches have been disappointingly nega-
tive, as none of these therapies has improved clinical out-
comes in sepsis and septic ARDS [6, 9–11].
The pathophysiology of ALI/ARDS in sepsis is the com-
plex result of the actions of circulating cellular elements
(e.g. polymorphonuclear leukocytes [PMN], platelets) and
soluble inflammatory mediators, such as lipopolysacchar-
ide (LPS) and multiple cytokines (e.g. tumour necrosis fac-
tor [TNF]α, interleukin [IL]1β), on multiple pulmonary
cellular targets [7, 8, 12]. These include tissue-resident in-
flammatory cells (e.g. alveolar macrophages), alveolar epi-
thelial cells, and the pulmonary vasculature, both large
vessels and especially the pulmonary microvasculature.
Septic microvascular dysfunction of both pulmonary and
systemic vascular beds is clinically important as it is
present early in the course of human sepsis and is associ-
ated with higher mortality [13–15], especially if persistent
over time [16].
Pulmonary microvascular injury and resulting dys-
function are characterized by increased pulmonary
microvascular PMN sequestration/adhesion as well as
disruption of the normal pulmonary microvascular
alveolo-capillary permeability barrier, resulting in
extra-vascular leak of protein-rich edema and PMN into
pulmonary interstitial and alveolar compartments and clin-
ically severe hypoxaemic respiratory failure [8, 17–23]. Sep-
tic pulmonary microvascular dysfunction is primarily the
result of the effects of septic inflammation on pulmonary
microvascular endothelial cells (PMVEC) [7, 13, 23–29].
There are several potential mechanisms of septic PMVEC
injury and dysfunction, including disruption of inter-
cellular junctions (e.g. adherens junctions), microtubule
activation, and actin cytoskeleton remodeling leading to
cell retraction and gap formation [30–33]. Our previous
work in a murine sepsis model identified that pulmonary
microvascular/PMVEC barrier dysfunction, as reflected by
enhanced albumin leak and oxidant stress required the
presence of both alveolar macrophages and PMN, CD18-
dependent PMN-PMVEC adhesion, increased nitric oxide
(NO) production from inducible NO synthase (iNOS),
and iNOS/NADPH oxidase-dependent peroxynitrite-
mediated signaling [17–19, 34–36].
Recently, we reported the first direct in vivo evidence of
septic PMVEC death, as observed by intravital videomi-
croscopy (IVVM) in septic mice [37]. Moreover, this
septic PMVEC death was associated with evidence of
apoptosis, as reflected by increased Annexin V binding,
caspase activation, and TUNEL staining. PMVEC apop-
tosis has been proposed in sepsis models [38, 39], and
could contribute to pulmonary microvascular albumin-
permeability barrier dysfunction [40, 41]. Indeed, in vivo
manipulation of various apoptosis pathways (e.g. the
Fas-Fas ligand pathway) in animal models of sepsis im-
proved measures of ALI severity suggesting a potential
importance of global apoptosis in septic ALI [42, 43].
However, the specific role of PMVEC death in sepsis-
induced ALI and septic pulmonary microvascular/
PMVEC dysfunction remains uncertain, as does the im-
portance of apoptosis in PMVEC death/dysfunction.
Thus, to further our previous studies, we first defined
the time course of the onset of septic pulmonary micro-
vascular barrier dysfunction in vivo in the murine cecal
ligation/perforation (CLP) model of sepsis, and corre-
lated this with the time course of PMVEC death as well
as 3 specific molecular markers of PMVEC apoptosis. In
addition, we assessed the effects of a specific, irreversible
broad-spectrum caspase inhibitor, Q-VD, on septic
PMVEC apoptotic death and septic pulmonary micro-
vascular barrier dysfunction. Finally, we assessed the
contribution of iNOS- and NADPH-oxidase-dependent
oxidant stress to both septic PMVEC barrier dysfunction
and death/apoptosis. Pulmonary microvascular Evans
blue (EB)-labeled albumin leak increased by 2 h and
peaked 4 h after CLP-induced sepsis, in parallel to and
directly correlated with significant septic PMVEC death
in vivo, as well as, and specifically, apoptosis. Moreover,
effective inhibition of PMVEC apoptosis using the
broad-spectrum caspase inhibitor, Q-VD, significantly at-
tenuated septic pulmonary microvascular dysfunction,
including both septic albumin hyper-permeability and
pulmonary microvascular PMN sequestration. Both sep-
tic PMVEC apoptosis and pulmonary microvascular/




All experimental animal protocols were performed in ac-
cordance with the Canadian Council on Animal Care
guidelines for the care and handling of animals. The
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institutional Animal Care and Use Committee approved
all studies (Approval # 2011–026), which were also
supervised by a veterinarian.
Animals
Male wild-type C57Bl/6, Nos2−/−, p47 phox−/−, and gp91phox
−/−mice (8–10 weeks, 25–30 g; Charles River, St. Constant,
Quebec) were randomized to volume-resuscitated CLP-
sepsis under inhaled isoflurane anesthesia vs. sham sur-
gery, as we previously described [17, 19, 37]. At 30 mins,
1, 2, and 4 h after surgery, mice were prepared for pul-
monary IVVM or sacrificed using a lethal dose of s/c
pentobarbital and exsanguination for lung formalin fix-
ation, collection, and histologic slide preparation [37].
Pulmonary microvascular albumin-permeability in vivo
Pulmonary microvascular albumin-permeability was
assessed by the EB dye technique, as we previously de-
scribed [18]. In brief, sham and CLP mice received tail
vein injections of EB (50 μg/g) 30 mins prior to sacrifice at
relevant time points. Following sacrifice, PBS-perfused
lungs were harvested, formamide-extracted, EB content
measured spectrophotometrically, and EB-albumin per-
meability calculated (μg EB/g lung/min).
Pulmonary IVVM
Pulmonary IVVM was performed as we previously de-
scribed [17]. In brief, anesthetized, tracheotomized,
mechanically ventilated mice had a 10 mm diameter
transparent window implanted in the right thoracic
wall, permitting inverted microscopy and visualization
of the sub-pleural pulmonary microcirculation (32 × 10.4
objective, DIAPHOT-300 epi-fluorescence microscope,
Nikon, Melville NY) and digital recording (Pixelfly QE
High Performance Monochrome Digital Camera System
with ICX-285 CCD, Opticon, Kitchener, ON).
Quantification of PMVEC Death/Apoptosis
PMVEC death was quantified using both IVVM and
lung tissue histology, as we previously described [37]. In
brief, propidium iodide (PI; 0.5 μg/g bodyweight; Sigma)
was intravenously injected immediately prior to IVVM
fluorescence microscopy imaging to label non-viable
PMVEC (excitation/emission: 530/590 nm). IVVM re-
sults were confirmed using fluorescence microscopy on
lung histological sections. All cell nuclei were stained
(Hoechst 33342; excitation/emission: 346/460 nm),
non-viable PI+ cells were quantified, and PMVEC were
identified by labeling with rat anti-mouse CD31 (BD
Pharmingen). In each of 3 lung sections per mouse, 3
random digital images were captured, and PI+/CD31+
PMVEC/high power field (hpf ) were quantified.
To identify features of apoptosis in PMVEC, three differ-
ent molecular markers were assessed using fluorescence
microscopy on lung tissue sections. (1) Loss of cell mem-
brane polarization (as indicated by presence of cell surface
phosphatidylserine) was assessed by injecting mice with
Annexin V (conjugated to Alexa Fluor 594; excitation/emis-
sion: 590/617 nm, Invitrogen, Burlington, Ontario) 30 mins
prior to sacrifice and lung tissue harvest for subsequent
imaging. (2) To detect caspase activation, mice were treated
30 mins prior to sacrifice with intravenous FAM-FLIVO
(excitation/emission: 490/525 nm; Immunohistochemistry
Technologies, Bloomington, Minnesota), which binds
activated caspases. (3) Late-stage apoptotic DNA frag-
mentation was examined by terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL; excita-
tion/emission: 494/521 nm; In Situ Cell Death Detection,
Roche, Laval, Quebec).
Separate cohorts of wild-type C57Bl/6 mice were
treated intravenously with the broad-spectrum potent
caspase-inhibitor quinoline-Val-Asp(Ome)-CH2-O-phe-
noxy (Q-VD, 1.0 μg/g bodyweight, APExBIO, Boston,
Massachusetts) [44] or a highly specific pharmacologic in-
hibitor of NADPH oxidase (apocynin, 20 μg/g bodyweight,
Abcam, Toronto, Ontario) [45] 30 mins prior to CLP-
septic vs. sham procedures.
Quantification of Pulmonary Microvascular
Polymorphonuclear (PMN) Leukocyte Sequestration
As we previously described, rhodamine-6-G-positive
PMN were quantified (rhodamine-6-G excitation/emis-
sion: 530/580 nm) [17, 18, 37]. Digital images were ob-
tained and rhodamine-6-G-positive cells were quantified.
Quantification of CLP-induced peritonitis
As in human sepsis and related ALI/ARDS, this murine
CLP model of septic ALI depends critically on the inten-
sity of the initial infectious focus, the CLP-induced peri-
tonitis. As experimental interventions, such as use of
genetically deficient mouse strains or pharmacologic an-
tagonists, could conceivably modify the initial peritoneal
infection or inflammatory response, the degree of peri-
tonitis following CLP vs. sham surgery was assessed
using 3 parameters, peritoneal wash bacterial concentra-
tion, total leukocyte counts, and protein levels, as previ-
ously reported [19, 46].
Statistical analysis
Data are mean ± SEM. Between-group differences were
assessed by t-test, one-way ANOVA with Tukey post-
hoc test, or two-way ANOVA with Bonferroni post-hoc
test, where appropriate. p < 0.05 was accepted as signifi-
cant. The correlation of time-dependent changes in pul-
monary microvascular EB-albumin permeability with
PMVEC death (PI+) or apoptosis (FLIVO+) was assessed
by Pearson’s method.
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Results
Time Course of Sepsis-induced PMVEC Barrier Dysfunction
and Death
As previously reported [17, 19], the murine CLP-model
of sepsis is characterized by significant clinical illness, as
septic mice exhibit huddling, piloerection, tachypnea,
and reduced exploratory behaviour. We first defined the
time course of early changes in pulmonary microvascu-
lar permeability in vivo over the first 30 mins – 4 h after
CLP-induced sepsis vs. sham surgery (Fig. 1a). In sham
mice, basal pulmonary microvascular endothelial perme-
ability, as reflected by lung tissue content of EB-dye-
labeled albumin, was 1.1 ± 0.2 μg EB/g lung/min, which
was not significantly different from 30 mins – 4 h after
sham procedures (data not shown). Immediately after
CLP-sepsis surgery (30 mins), pulmonary microvascu-
lar endothelial EB-albumin permeability was slightly,
but not significantly greater than in sham mice, at
1.4 ± 0.3 μg EB/g lung/min. By 2 h post-CLP, septic mice
had evidence of significant pulmonary microvascular endo-
thelial barrier dysfunction compared to sham-treated mice,
and this difference was more marked at 2.7 ± 0.4 μg EB/g
lung/min by 4 h after CLP-sepsis (Fig. 1a).
We next assessed the time course of septic PMVEC
death in vivo with pulmonary IVVM and ex vivo in lung
tissue sections over the first 30 mins – 4 h after CLP-
induced sepsis vs. sham surgery (Fig. 1b). In sham mice,
there was a low basal rate of PMVEC death (PI+ staining;
2.5 ± 0.5 cells/hpf, and 99 ± 1 % of these non-viable cells
were PMVEC, identified through PI+/CD31+ double-
staining overlap. Overall, 8 ± 1 % of CD31+ PMVEC were
also PI+ in sham mice, and this low basal level of PMVEC
death was similar between 30 mins and 4 h after sham
surgery (data not shown). Following CLP-induced sepsis,
PMVEC death (number PI+/hpf) was significantly in-
creased at 2 and 4 h after CLP-sepsis compared to sham.
As in sham mice, these PI+/dead cells were almost uni-
formly PMVEC, based on PI+/CD31+ double-staining
overlap in 95 ± 3 %. In contrast to sham mice, PI+/dead
PMVEC represented a sizable proportion, 71 ± 5 %, of all
PMVEC/hpf at 4 h after CLP-sepsis.
Septic PMVEC death (PI+ staining) post-CLP appeared
to be almost completely due to PMVEC apoptosis, based
on fluorescent microscopy of lung tissue sections. The
earliest measurable apoptotic signals were increases in both
PMVEC FLIVO staining (caspase activation) and Annexin
V staining at 30 mins after CLP-sepsis (Fig. 1c). PMVEC
apoptosis appears to have increased progressively until 4 h
after CLP-sepsis, at which time point there was strong evi-
dence of septic PMVEC apoptosis as quantified by all 3 mo-
lecular markers of apoptosis: enhanced Annexin V binding,
FLIVO staining, and TUNEL presence. There was a high
degree of overlap between the 2 earliest markers of
apoptosis (Annexin V binding and FLIVO staining) at 4 h
after CLP-sepsis (Fig. 2): 100 ± 0 % of Annexin V+ PMVEC
were also FLIVO+, and 93 ± 3 % of FLIVO+ PMVEC were
Annexin V+. In contrast, only 74 ± 5 % of TUNEL+
Fig. 1 Time course of pulmonary microvascular endothelial cell (PMVEC)
albumin-permeability barrier dysfunction, death and apoptosis following
cecal ligation/perforation (CLP)-sepsis in mice in vivo. a The leak of Evans
blue (EB) dye-labeled albumin into lung tissue increased 2 and 4 h after
CLP-induced sepsis, compared to sham control mice. n= 14 (Sham) and
n= 3–10 /time point (CLP). b PMVEC death, as assessed through nuclear
propidium iodide (PI+) staining visualized by fluorescence intravital
videomicroscopy, was observed 2 and 4 h after CLP-induced sepsis,
compared to sham control mice. n = 6 (Sham; combined 0.5 and
4 h time points) and n = 3–9 /time point (CLP). c PMVEC apoptosis
was quantified by 3 complementary molecular markers: phosphatidyl
serine expression (Annexin V+ staining), caspase activation (FLIVO+
staining), and DNA fragmentation (TUNEL+ labeling). Compared to
low-level PMVEC apoptosis in sham control mice, enhanced septic
PMVEC apoptosis was observed 0.5 – 1 h after CLP-induced sepsis and
increased in time-dependent manner until 4 h. n = 6 (Sham; combined
0.5 and 4 h time points) and n = 3–9 /time point (CLP). *p < 0.05 and
**p < 0.01 for CLP vs. sham group
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PMVEC were also FLIVO+, and conversely, 65 ± 1 % of
FLIVO+ PMVEC were also TUNEL+.
Role of PMVEC Death/Apoptosis in Sepsis-Induced PMVEC
Barrier Dysfunction
Following CLP-sepsis, the time-dependent disruption
of pulmonary microvascular/PMVEC barrier function,
as reflected by pulmonary microvascular EB-albumin
permeability in vivo, was strongly correlated (r = 0.976,
p < 0.05; Fig. 3a) with IVVM PMVEC death (PI+). More-
over, pulmonary microvascular EB-albumin permeability
was also highly correlated specifically with histologic
markers of PMVEC apoptosis, including caspase activation
(FLIVO+ staining; r = 0.991, p < 0.05; Fig. 3b), Annexin V+
labeling (r = 0.938, p < 0.05), and TUNEL+ labeling (r =
0.987, p < 0.05).
The specific role of septic PMVEC apoptosis in septic
pulmonary microvascular/PMVEC barrier dysfunction in
vivo was pursued by inhibiting apoptosis using the
broadly-selective, irreversible pharmacologic antagonist of
activated caspases, Q-VD. Treatment of sham mice with
either Q-VD or the DMSO solvent control had no effects
on the normal pulmonary microvascular/PMVEC EB-
albumin permeability in vivo or the low, basal levels of
PMVEC death (PI+) or apoptosis (FLIVO+, Annexin V+,
TUNEL+; Fig. 4). In contrast, Q-VD treatment prior to
CLP-sepsis surgery significantly attenuated septic pulmon-
ary microvascular/PMVEC permeability barrier dysfunc-
tion (Fig. 4a) as well as septic increases in both PMVEC
death (decreased PI+ staining; Fig. 4b) and specifically
apoptosis as reflected by decreased presence of FLIVO,
Annexin V, and TUNEL labeling (Fig. 4c and d).
Role of iNOS and NADPH oxidase in Sepsis-induced
PMVEC apoptosis
We have previously reported that iNOS plays an import-
ant role in multiple features of septic ALI in the murine
CLP-sepsis model, including pulmonary microvascular
endothelial barrier dysfunction and the resulting albumin
hyper-permeability, pulmonary oxidant stress, pulmonary
microvascular PMN sequestration and trans-PMVEC
PMN migration [17, 18, 35, 47]. Thus, we assessed the
Fig. 2 Evidence of PMVEC apoptosis 4 h following CLP-sepsis in mice in vivo. a PMVEC in ex vivo lung tissue sections were labeled with a specific
marker (CD31; left column of panels; red). Activated caspases were identified by labeling with FLIVO (middle column of panels; green). Compared to
sham mice in which only a few PMVEC stained positive for activated caspases, CLP-sepsis markedly increased the number PMVEC with activated
caspases (overlay; right column of panels). b Compared to sham mice, CLP-sepsis was associated with increased PMVEC apoptosis as identified using
three complementary markers: FLIVO (activated caspases), Annexin V (surface phosphatidyl serine presence), and TUNEL (DNA fragmentation). At 4 h
following CLP-sepsis, FLIVO+ PMVEC (green) were almost uniformly also Annexin V+ (left column of panels), and were largely but not always
TUNEL+ (right column of panels). Scale bar = 20 μm
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contribution of iNOS to septic PMVEC apoptosis in CLP-
sepsis vs. sham mice. We first confirmed that septic pul-
monary microvascular/PMVEC barrier dysfunction was
prevented in mice lacking iNOS (Nos2−/−) undergoing CLP
surgery (Fig. 5a). Similarly, septic PMVEC death (PI+) in
wild-type mice was also abrogated in septic Nos2−/− mice
(Fig. 5b). Furthermore, reduced PMVEC FLIVO+ and
TUNEL+ staining (Fig. 5c) in septic Nos2−/− mice confirm
that the reduction in PMVEC death was specifically due to
a decrease in PMVEC apoptosis in septic Nos2−/− mice vs.
wild-type mice.
Similarly, the role of NADPH oxidase in septic pul-
monary microvascular/PMVEC barrier dysfunction and
PMVEC death/apoptosis was defined by comparing sep-
tic responses in wild-type mice vs. mice deficient in
functional NADPH oxidase (gp91phox−/− and p47 phox−/−).
Compared to CLP-septic wild-type mice, septic pulmon-
ary microvascular/PMVEC EB-albumin permeability bar-
rier dysfunction in vivo was attenuated in septic gp91phox
−/− and p47phox−/− mice (Fig. 6a). In parallel, septic
PMVEC death (PI+ staining; Fig. 6b) and apoptosis
(TUNEL+ staining; Fig. 6c), were also inhibited in septic
gp91phox−/− and p47 phox−/− vs. wild-type mice. Moreover,
the role of NADPH oxidase was confirmed by quantify-
ing the effects of NADPH oxidase pharmacologic inhib-
ition using apocynin. Pre-treatment of wild-type mice
with apocynin prior to CLP-sepsis surgery similarly abro-
gated the septic increases in pulmonary microvascular/
PMVEC EB-albumin permeability, PMVEC death (PI+)
and apoptosis (TUNEL+) (Fig. 6a, b, c), similar to the ob-
servations in septic NADPH oxidase-deficient mouse
strains. Apocynin inhibition of CLP-septic PMVEC
apoptosis was further confirmed by demonstrating
complete attenuation of septic PMVEC FLIVO+ staining
(3 ± 1 cells /hpf, p < 0.05 vs. septic wild-type) and Annexin
V+ staining (3 ± 1 cells /hpf, p < 0.05 vs. septic wild-type),
with 99 ± 1 % overlap between the 2 apoptosis markers.
Effects of Sepsis and PMVEC Apoptosis on Pulmonary
Microvascular PMN Sequestration
We have previously demonstrated that pulmonary micro-
vascular dysfunction in the murine CLP-sepsis model is
also characterized by significantly enhanced pulmonary
microvascular PMN sequestration [17, 37]. Thus, we fur-
ther examined the relationship between this CLP-septic
pulmonary microvascular PMN sequestration and septic
PMVEC death/apoptosis. We confirmed our previous
reports of a marked increase in the number of rhodamine-
6-G-labeled PMN sequestered in the pulmonary microvas-
culature in vivo (by IVVM; Fig. 7) in CLP-septic wild-type
vs. sham mice, and confirmed this ex vivo by fluorescence
microscopy in lung histologic sections (data not shown).
This feature of septic pulmonary microvascular dysfunc-
tion, specifically enhanced PMN sequestration, was signifi-
cantly attenuated following: (a) inhibition of caspases with
Q-VD pre-treatment of wild-type mice prior to induction
of CLP-sepsis, (b) CLP-sepsis in gp91phox−/− and p47phox−/−
mice, and (c) inhibition of NADPH oxidase with apocynin
pre-treatment of wild-type mice prior to CLP-sepsis. Simi-
larly, we have previously reported that this CLP-septic pul-
monary microvascular PMN sequestration was inhibited in
septic Nos2−/− vs. wild-type mice [17, 37].
CLP-Induced Peritonitis and Effects of Experimental
Interventions
CLP surgery was associated with purulent peritonitis on
gross inspection, which was confirmed by significant
bacterial presence and quantitative increases in periton-
eal protein levels and total cell counts in all CLP-septic
groups vs. respective sham groups (Table 1). CLP-sepsis
resulted in slightly lower peritoneal total cell counts in
Q-VD treated vs. control DMSO-treated CLP-septic
mice. Otherwise, the intensity of CLP-induced peritoneal
infection and inflammation was not significantly differ-
ent between control DMSO-treated CLP-septic mice,
pharmacologically-treated CLP-septic groups (Q-VD,
apocynin), or CLP-septic gp91phox−/− and p47 phox−/−
Fig. 3 Correlation of time-dependent changes in septic PMVEC
albumin-permeability barrier dysfunction with (a) PMVEC death
(PI+ staining) and (b) PMVEC apoptosis (FLIVO+ staining) following
CLP-sepsis in mice in vivo. Open symbols (sham, n = 6), filled symbols
(CLP, n = 3–9 /time point)
Gill et al. Respiratory Research  (2015) 16:109 Page 6 of 13
groups. We have previously reported similar data on the
lack of any difference in CLP-induced peritonitis be-
tween septic wild-type and Nos2−/− mice [19].
Discussion
In the murine CLP-septic ALI model, pulmonary micro-
vascular/PMVEC barrier dysfunction in vivo and resulting
albumin hyper-permeability developed rapidly over 2–4 h
after CLP-sepsis, with a similar time course as PMVEC
death, as reflected by PI+ staining, and with specific fea-
tures consistent with PMVEC apoptosis, including surface
phosphatidyl serine presence (Annexin V staining), cas-
pase activation (FLIVO staining), and DNA fragmentation
(TUNEL labeling). Moreover, septic pulmonary micro-
vascular/PMVEC barrier dysfunction correlated strongly
with measures of PMVEC death/apoptosis. Pharmacologic
caspase inhibition with Q-VD in vivo prior to CLP
significantly prevented septic PMVEC death/apoptosis
and attenuated septic pulmonary microvascular/PMVEC
dysfunction, as reflected by both reduced albumin-
permeability barrier dysfunction and pulmonary micro-
vascular PMN sequestration. Septic PMVEC apoptosis
and microvascular/PMVEC dysfunction in vivo were
both similarly abolished following CLP-sepsis in mice
lacking iNOS (Nos2−/−) or NADPH oxidase activity
(p47phox−/− and gp91phox−/−), as well as in wild-type mice
pre-treated with the NADPH oxidase pharmacologic in-
hibitor, apocynin. Thus, septic pulmonary microvascular/
PMVEC dysfunction including high-albumin pulmonary
edema and enhanced PMN sequestration, key pathophysi-
ologic features of septic ALI, appear to be the result of
PMVEC death specifically due to caspase-dependent
apoptosis, which appears to be mediated through the ac-
tivity of both iNOS and NADPH oxidase.
The high morbidity and mortality of sepsis are the re-
sult of multiple organ dysfunction/failure, including
ALI/ARDS, which is due in large part to septic injury
and dysfunction of the microvasculature and especially
MVEC [2, 4, 5, 48]. Septic microvascular/MVEC injury
and dysfunction are characterized pathophysiologically
by perturbed microvascular distribution of blood flow in
many organs, enhanced microvascular thrombosis, en-
hanced PMN-MVEC interaction, and disruption of the
normal microvascular/MVEC permeability barrier,
resulting in high-permeability albumin-rich tissue and
organ edema [13, 14, 17–21, 30, 48–53]. The severe
hypoxaemic respiratory failure of ALI/ARDS is patho-
physiologically due to pulmonary microvascular PMN
Fig. 4 Role of PMVEC apoptosis in septic pulmonary microvascular permeability barrier dysfunction. a Treatment of wild-type mice with the
multi-caspase inhibitor Q-VD inhibited septic pulmonary microvascular EB-albumin leak at 4 h following CLP-sepsis. Q-VD treatment also markedly
attenuated septic PMVEC death (PI+; panel b) and PMVEC apoptosis (FLIVO+, Annexin V+, TUNEL+; panels c and d) at 4 h following CLP-sepsis.
n = 3-4 (Sham) and n = 4-6 (CLP). * p < 0.05, CLP vs. respective sham group; #, p < 0.05 Q-VD-treated vs. untreated CLP. Scale bar = 20 μm
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sequestration and influx into pulmonary interstitial and
alveolar compartments, mediated through enhanced PMN-
PMVEC adhesion, and the associated injury and dysfunc-
tion of the pulmonary microvascular alveolo-capillary
permeability barrier and resulting extra-vascular leak of
protein-rich edema [17–21, 51].
In ALI/ARDS, pathologic disturbances have been de-
scribed in the structure and function of both key cells in
the normal alveolo-capillary permeability barrier, namely
PMVEC and alveolar epithelial cells (AEC) [54, 55]. For
example, AEC dysfunction in ALI/ARDS is characterized
by impairment of their normal barrier and alveolar water
clearance functions, which is associated with worse out-
come in ARDS patients [56]. Moreover, AEC also con-
tribute to inflammation in ALI/ARDS, as they are an
important source of cytokines and chemokines [54],
and also foster intra-alveolar coagulation [57, 58]. Hu-
man AEC may also have a critical role in protecting
adjacent human PMVEC against septic injury through
a paracrine mechanism, as we recently described in
human PMVEC-AEC co-cultures in vitro [59].
Most importantly in sepsis, injury and dysfunction of the
pulmonary microvasculature and specifically PMVEC are
central to the pathophysiology of septic ALI. Our previous
work has established in murine CLP-sepsis that pulmonary
microvascular/PMVEC permeability barrier dysfunction
requires the presence of PMN and alveolar macrophages,
PMN-PMVEC CD18-dependent adhesion, as well as func-
tional iNOS and NADPH oxidase [17–19, 34–36]. More-
over, this in vivo murine CLP-septic ALI model is
characterized by pulmonary oxidant and specifically nitro-
sative stress, consistent with NO-superoxide reaction and
Fig. 5 Role of iNOS in septic PMVEC permeability barrier dysfunction,
death and apoptosis 4 h following CLP-sepsis in mice in vivo. As
compared to septic wild-type (WT) mice, iNOS deficiency (Nos2−/−)
was associated with complete attenuation of septic increases in
(a) pulmonary microvascular EB-albumin leak, (b) PMVEC death,
and (c) PMVEC apoptosis (FLIVO+, TUNEL+). n = 3–4 (Sham) and
n = 3–6 (CLP). * p < 0.05 and ** p<0.01, CLP vs. respective sham
group; # p < 0.05, Nos2−/− vs. wild-type CLP
Fig. 6 Role of NADPH oxidase in septic PMVEC permeability barrier
dysfunction, death and apoptosis 4 h following CLP-sepsis in mice in
vivo. As compared to septic WT mice, NADPH oxidase deficiency (both
gp91phox−/− and p47phox−/−) or inhibition (apocynin) was associated
with complete attenuation of septic increases in (a) pulmonary
microvascular EB-albumin leak, (b) PMVEC death, and (c) PMVEC apoptosis
(TUNEL+). n= 3–4 (Sham) and n= 3–6 (CLP). * p< 0.05 and ** p<0.01, CLP
vs. respective sham group; #, p< 0.05 vs. wild-type CLP
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peroxynitrite generation [35]. Consistent with the in vivo
findings, cultured murine and human PMVEC under
septic conditions exhibit permeability barrier dysfunc-
tion, which is similarly enhanced by the presence of
PMN and macrophages in co-culture, requires PMN-
PMVEC CD18-dependent adhesion and specifically the
presence of functional iNOS in PMN and macrophages
[60–64]. Most recently, we pursued the potential crit-
ical role of putative PMVEC death in the CLP-septic
murine model in vivo [37].
The death of cells in pathologic conditions is an increas-
ingly important and complex research topic, as there are
now as many as 10 different mechanisms, e.g. apoptosis,
necrosis, necroptosis, pyroptosis, and autophagy [65, 66].
The specific mechanisms through which cells ultimately
die depend upon many factors, including the nature of the
initial injurious stimulus, the specific cell type, and the
time point assessed, and are best identified by specific mo-
lecular markers (e.g. caspase 3/7 activation and DNA frag-
mentation [TUNEL+] with apoptosis, caspase 1 activation
in pyroptosis, DNA fragmentation in the absence of cas-
pase activation in necrosis) [65–67]. The death of EC can
be through many of these mechanisms, although evi-
dence for many mechanisms is largely derived from
study in vitro. For instance, bacterial infection is associ-
ated with increased autophagy, sepsis can be associated
with evidence of both apoptosis and necrosis, and in-
flammation following blood transfusion or lung infec-
tion has been found to cause necroptosis as well as
pyroptosis [37, 68–71].
Although it is often stated that there is enhanced EC
death in sepsis, this remains controversial, as evidence is
relatively sparse, especially direct in vivo data in clinic-
ally relevant models of sepsis (e.g. CLP). Few studies
have reported quantification of apoptotic EC specifically
under septic conditions [38, 41, 43, 72], possibly due to
the shedding of such apoptotic EC from the microvascu-
lature [39]. Moreover, various septic models have been
used, e.g. intravenous or intra-peritoneal LPS adminis-
tration, some of which may not capture the complex
pathophysiology of bacterial sepsis and septic ALI. In
addition, identification of apoptotic cells has often been
with a single marker of apoptosis (e.g. TUNEL staining),
and confirmation of EC-specific apoptosis using double-
staining with EC-specific markers has rarely been re-
ported. Specifically in humans, there is limited direct
evidence for septic EC death/apoptosis, which is largely
supported by increased levels of circulating ECs and
plasma caspase 3 [73, 74].
In the murine CLP-sepsis model, we recently re-
ported significant septic PMVEC death (PI+ PMVEC
confirmed through double-labeling with CD31, CD34,
and G. simplicifolia lectin) as observed by IVVM and
confirmed by pulmonary histology [37]. Moreover,
Fig. 7 Effects of CLP-sepsis, Q-VD treatment (caspase inhibition), and
NADPH oxidase deficiency or inhibition on pulmonary microvascular
polymorphonuclear leukocyte (PMN) sequestration in murine sepsis in
vivo. In septic WT mice, pulmonary microvascular/PMVEC dysfunction
is associated with dramatic increases in pulmonary microvascular
PMN sequestration, as assessed by rhodamine-6-G (Rh+) labeling
and visualization by fluorescence IVVM. This septic pulmonary
microvascular / PMVEC dysfunction and resulting increased PMN
sequestration were markedly attenuated following caspase inhibition
(Q-VD treatment in CLP-WT mice), in septic gp91phox−/− and p47phox−/−
mice, and following NADPH oxidase inhibition (apocynin treatment in
CLP-WT mice). n = 2-3 (Sham) and n = 3-4 (CLP). * p < 0.05, CLP vs.
respective sham group; #, p < 0.05 vs. WT CLP





Protein Bacterial load Total Cells Protein Bacterial load Total Cells
(mg/mL) (104 CFU/mL) (107/mL) (mg/mL) (104 CFU/mL) (107/mL)
Wild-Type
DMSO 0.6 ± 0.1 0.0 ± 0.0 0.07 ± 0.01 2.2 ± 0.2 5.4 ± 0.7 3.6 ± 0.2
Q-VD 0.7 ± 0.1 0.0 ± 0.0 0.07 ± 0.01 2.1 ± 0.1 5.4 ± 1.1 2.5 ± 0.1 *
NADPH oxidase deficient
p47phox−/− 1.0 ± 0.3 0.3 ± 0.3 0.12 ± 0.04 2.4 ± 0.5 5.9 ± 1.2 3.3 ± 0.3
gp91−/− 1.1 ± 0.4 0.2 ± 0.3 0.15 ± 0.05 2.6 ± 0.7 6.4 ± 1.5 2.9 ± 0.4
*, p < 0.05 vs. DMSO control CLP group
CFUs indicate colony-forming units
Gill et al. Respiratory Research  (2015) 16:109 Page 9 of 13
septic PMVEC death appeared to be largely due to
PMVEC apoptosis, as reflected by high degrees of over-
lap on double-staining with increased Annexin V bind-
ing, FLIVO (caspase activation) and TUNEL (DNA
fragmentation) staining. However, the putative direct
role of PMVEC death in septic ALI, specifically in vivo
pulmonary microvascular/PMVEC dysfunction, had not
yet been clearly defined.
Cell death can be both beneficial (promotes recovery
and prevents injury propagation) and detrimental (pro-
motes loss of tissue function and inhibits repair),
dependent again on the nature of the injury and the cell
type. Death of EC, especially MVEC, has been proposed
as an important mechanism of septic microvascular/
MVEC dysfunction. In the current study, three lines of
evidence solidly support an essential role of PMVEC
death/apoptosis in murine septic pulmonary microvascu-
lar/PMVEC dysfunction in vivo: (a) following CLP-sepsis,
pulmonary microvascular/PMVEC barrier dysfunction
and PMVEC death/apoptosis followed parallel time
courses; (b) there were strong correlations between in vivo
septic pulmonary microvascular/PMVEC barrier dysfunc-
tion and both PMVEC death (PI+) and markers of apop-
tosis (e.g. FLIVO+); and (c) irreversible pan-caspase
pharmacologic inhibition with Q-VD markedly blunted
septic PMVEC death/apoptosis and attenuated in vivo
septic pulmonary microvascular/PMVEC dysfunction, in-
cluding both albumin-permeability barrier dysfunction
and pulmonary microvascular PMN sequestration.
Our previous work and the present study suggest
caspase-dependent apoptosis as the most likely mechan-
ism of PMVEC death in murine sepsis. The specific and
rigorous characterization of apoptosis is important, as
individual molecular markers commonly used to define
apoptosis can be present during non-apoptotic cell death
and even under inflammatory non-death conditions. In
fact, it is widely accepted that apoptosis should be de-
fined using multiple molecular markers [65, 66], and
thus, in the current study, three distinct markers were
used to define apoptosis: Annexin V (surface phosphati-
dylserine localization), FLIVO (caspase activation), and
TUNEL labeling (DNA fragmentation). Furthermore, the
effects of the potent caspase pharmacologic inhibitor Q-
VD in markedly attenuating PMVEC apoptosis (by all
three markers) confirms our putative role for PMVEC
caspase-dependent apoptosis in PMVEC death and sep-
tic pulmonary microvascular/PMVEC dysfunction. Our
findings are consistent with previous work on the role of
caspase activation in EC apoptosis in vivo [42, 43, 75].
The present study also demonstrated that both iNOS
and NADPH oxidase expression/activity were essential
to murine septic PMVEC death/apoptosis, and the
resulting in vivo pulmonary microvascular/PMVEC dys-
function. Septic upregulation of iNOS expression and
activity have been recognized to contribute to pulmon-
ary cell apoptosis [76]. For example, both Nos2−/− mice
and iNOS-inhibited wild-type mice had decreased num-
bers of apoptotic alveolar and bronchiolar epithelial cells
following sepsis [76]. The vital chemical interplay be-
tween these 2 key oxidant mediator systems, iNOS-NO
and NADPH oxidase-superoxide, has long been recog-
nized in sepsis and ALI pathophysiology. NO and super-
oxide react extremely quickly to generate the highly
potent oxidant peroxynitrite, which serves many physio-
logic and pathophysiologic functions [77, 78]. The cen-
tral role of iNOS- and NADPH oxidase-signaling in
septic PMVEC death/dysfunction in the present study is
consistent with our previous data on septic murine pul-
monary microvascular/PMVEC barrier dysfunction in
vivo being associated with pulmonary oxidant and nitro-
sative stress [35]. Likewise, in vitro human PMVEC bar-
rier dysfunction and PMN-PMVEC adhesion under septic
conditions were also dependent on NO, superoxide, and
peroxynitrite [63]. It is also clear that NADPH oxidase
could contribute to apoptosis through multiple potential
mechanisms, including through superoxide-dependent
modulation of the expression of the cell cycle regulators,
p21cip1 and p53, as well as through increased expression
of CCAAT-enhancer-binding protein homologous protein
(CHOP) [79, 80]. Additionally, we have shown that
NADPH oxidase-dependent oxidant stress can mediate
calpain-dependent caspase activity and apoptosis in septic
murine PMVEC in vitro [40].
A central role for PMN in many of the pathophysiologic
features of septic ALI in animal models, as well as in hu-
man ARDS has been clearly established [21, 81–83]. We
and others have reported that septic pulmonary micro-
vascular/PMVEC barrier dysfunction in mice in vivo and
in murine and human PMVEC in vitro is clearly PMN-
dependent [17, 18, 21, 35, 37, 60, 61, 84], and our recent
study also strongly implicated pulmonary microvascular
PMN leukocyte sequestration and CD18-dependent
PMN-PMVEC adhesion in septic PMVEC death [37].
There are several contributory mechanisms of PMN-
dependent pulmonary microvascular/PMVEC dysfunction
including PMN-PMVEC physical interaction, release of
PMN mediators (i.e. oxidants and proteases), and release
of PMN extracellular traps [21, 85]. One of the key re-
quirements for PMN-dependent pulmonary microvascu-
lar/PMVEC dysfunction appears to be the pulmonary
microvascular PMN sequestration and PMN-PMVEC ad-
hesion [17, 63, 84]. Intriguingly, in the present study, re-
duced PMVEC death/apoptosis in response to various
interventions (e.g. Q-VD caspase inhibition, NADPH oxi-
dase deficiency/inhibition) was associated with reduced
pulmonary microvascular PMN sequestration, similar to
our previous findings in septic Nos2−/− mice [17, 37]. This
suggests that septic PMVEC undergoing death/
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apoptosis may not be as immunologically “silent” or
tolerogenic as initially thought [86], but may signal
both adaptive immunity as well as paracrine inflamma-
tory and pro-coagulant responses [87, 88].
We recognize the limitations of our study. Pulmonary
microvascular barrier function is a complex system, and
multiple mechanisms of septic ALI and specifically EC
injury and dysfunction have been described in various
animal models of sepsis/ALI in vivo and in isolated EC
(including human EC models) under septic conditions in
vitro. These include roles for altered cell-cell and cell-
matrix (eg. glycocalyx) interactions, endogenous inflam-
matory cytokines (eg. TNFα) and vaso-active mediators
(eg. vascular endothelial cell growth factor [VEGF],
angiopoietins, endothelin), and cytoskeletal rearrange-
ments [31–33]. We report that PMVEC death/apoptosis
contribute importantly to septic pulmonary microvascu-
lar/PMVEC barrier dysfunction, but appreciate that our
data do not exclude a role for other potential mecha-
nisms that may also play a role, either directly or pos-
sibly indirectly through PMVEC death/apoptosis. For
example, microvessel burn-induced decreased surface
VE-cadherin localization and disrupted VEGF-signaling
contribute to EC apoptosis, highlighting the potential
cross-talk between various mechanisms of EC barrier dys-
function [89]. Similarly, it is clear that iNOS-dependent
responses are complex and could contribute to pulmonary
microvascular/PMVEC barrier dysfunction through other
potential mechanisms, including modulation of inflamma-
tory signaling (eg. NF-kB) and nitrosylation and/or nitra-
tion of multiple cell-surface and intracellular protein
targets [34, 90, 91]. Finally, it should be noted that apocy-
nin, a pharmacologic antagonist of NADPH oxidase, was
used to confirm reduced PMVEC death/dysfunction in
NADPH oxidase deficient mice, but apocynin also has
anti-oxidant properties that may have contributed to its
observed effects [92].
Conclusions
We have shown for the first time in an in vivo murine sep-
tic ALI model that pulmonary microvascular/PMVEC
dysfunction, resulting in microvascular PMN sequestra-
tion and albumin hyper-permeability in vivo, are due to
septic PMVEC death and specifically caspase-dependent
apoptosis. This septic PMVEC death/apoptosis and result-
ing pulmonary microvascular/PMVEC dysfunction were
iNOS- and NADPH oxidase-dependent. Future studies
will further define the contributory molecular pathways of
septic PMVEC apoptosis and explore the potential clinical
and therapeutic importance of septic PMVEC apoptosis in
human sepsis/ARDS.
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